GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (NAS:TLIS) » Definitions » Price-to-Owner-Earnings

Talis Biomedical (Talis Biomedical) Price-to-Owner-Earnings : (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Price-to-Owner-Earnings?

As of today (2024-05-24), Talis Biomedical's share price is $9.00. Talis Biomedical does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Talis Biomedical's Price-to-Owner-Earnings or its related term are showing as below:


TLIS's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.29
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-24), Talis Biomedical's share price is $9.00. Talis Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-31.43. Therefore, Talis Biomedical's PE Ratio for today is At Loss.

As of today (2024-05-24), Talis Biomedical's share price is $9.00. Talis Biomedical's EPS without NRI for the trailing twelve months (TTM) ended in was $-31.43. Therefore, Talis Biomedical's PE Ratio without NRI for today is At Loss.


Talis Biomedical Price-to-Owner-Earnings Historical Data

The historical data trend for Talis Biomedical's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Price-to-Owner-Earnings Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Talis Biomedical Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Talis Biomedical's Price-to-Owner-Earnings

For the Medical Devices subindustry, Talis Biomedical's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talis Biomedical's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Price-to-Owner-Earnings falls into.



Talis Biomedical Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Talis Biomedical's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.00/-33.90
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talis Biomedical  (NAS:TLIS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Talis Biomedical Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Talis Biomedical (Talis Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3400 Bridge Parkway, Redwood City, CA, USA, 94065
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063